MEDICAL POLICY No R0
|
|
- Melvyn Weaver
- 5 years ago
- Views:
Transcription
1 TRANSCUTANEOUS ELECTRICAL ACUSTIMULATION (TEAS) FOR HYPEREMESIS GRAVIDARUM Effective Date: November 19, 2010 Review Dates: 10/10, 10/11, 10/12, 10/13, 11/14, 11/15, 11/16 Date Of Origin: October 13, 2010 Status: Current I. POLICY/CRITERIA TEAS devices (i.e. prescription version PrimaBella TM or ReliefBand devices) are considered to be medically necessary for the treatment of hyperemesis gravidarum that is unresponsive to other conservative medical therapy (e.g., change in diet, ginger capsules, vitamin B6). Over-the-counter disposable TEAS devices, which are used for the treatment of motion sickness are not considered to be medically necessary and are not a covered benefit. II. MEDICAL NECESSITY REVIEW Required Not Required Not Applicable III. APPLICATION TO PRODUCTS Coverage is subject to member s specific benefits. Group specific policy will supersede this policy when applicable. HMO/EPO: This policy applies to insured HMO/EPO plans. POS: This policy applies to insured POS plans. PPO: This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern. ASO: For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern. INDIVIDUAL: For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern. MEDICARE: Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, this policy applies. MEDICAID/HEALTHY MICHIGAN PLAN: For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule located at: If there is a discrepancy between Page 1 of 5
2 this policy and the Michigan Medicaid Provider Manual located at: the Michigan Medicaid Provider Manual will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage. IV. DESCRIPTION Up to 90% of pregnant women experience nausea and vomiting. When prolonged or severe, this is known as hyperemesis gravidarum (HG), which can, in individual cases, be life threatening. The etiology of HG is unknown in most cases, although some biological, physiological and psychological as well as sociocultural factors are thought to be contributory factors. Risk factors for HG include multiple pregnancy, nulliparity, obesity, metabolic disturbances, a history of HG in a previous pregnancy, trophoblastic disorders, psychological disorders (for example, eating disorders such as anorexia nervosa or bulimia) and a history of migration. For initial management, dietary and lifestyle advice is often sufficient to ameliorate symptoms and improve quality of life. TEAS devices emit a low-level electrical current across two small electrodes on their underside, stimulating the median nerve (an acupuncture point). V. CODING INFORMATION ICD-10 Codes that may support medical necessity: O21.0 Mild hyperemesis gravidarum O21.1 Hyperemesis gravidarum with metabolic disturbance O21.2 Late vomiting of pregnancy O21.8 Other vomiting complicating pregnancy O21.9 Vomiting of pregnancy, unspecified CPT/HCPCS Codes: E0765 FDA approved nerve stimulator, with replaceable batteries, for treatment of nausea and vomiting (Not covered for Priority Health Medicaid/Healthy Michigan Plan members) Page 2 of 5
3 VI. REFERENCES 1. Ho CM, Hseu SS, Tsai SK, Lee TY. Effect of P-6 acupressure on prevention of nausea and vomiting after epidural morphine for post-cesarean section pain relief. Acta Anaesthesiol Scand. 1996;40(3): Fan CF, Tanhui E, Joshi S, et al. Acupressure treatment for prevention of postoperative nausea and vomiting. Anesth Analg. 1997;84(4): Gralla RJ. Antiemetic therapy. Semin Oncol. 1998;25(5): Shenkman Z, Holzman RS, Kim C, et al. Acupressure-acupuncture antiemetic prophylaxis in children undergoing tonsillectomy. Anesthesiology. 1999;90(5): Lee A, Done ML. The use of nonpharmacologic techniques to prevent postoperative nausea and vomiting: A meta-analysis. Anesth Analg. 1999;88(6): Alkaissi A, Stalnert M, Kalman S. Effect and placebo effect of acupressure (P6) on nausea and vomiting after outpatient gynaecological surgery. Acta Anaesthesiol Scand. 1999;43(3): Pearl ML, Fischer M, McCauley DL, et al. Transcutaneous electrical nerve stimulation as an adjunct for controlling chemotherapy-induced nausea and vomiting in gynecologic oncology patients. Cancer Nurs. 1999;22(4): Alberta Heritage Foundation for Medical Research (AHFMR). ReliefBand. Techscan. Edmonton, AB: Alberta Heritage Foundation for Medical Research (AHFMR); March Zarate E, Mingus M, White PF, et al. The use of transcutaneous acupoint electrical stimulation for preventing nausea and vomiting after laparoscopic surgery. Anesth Analg. 2001;92(3): Slotnick RN. Safe, successful nausea suppression in early pregnancy with P-6 acustimulation. J Reprod Med. 2001;46(9): White PF, Issioui T, Hu J, et al. Comparative efficacy of acustimulation (ReliefBand) versus ondansetron (Zofran) in combination with droperidol for preventing nausea and vomiting. Anesthesiology. 2002;97(5): Coloma M, White PF, Ogunnaike BO, et al. Comparison of acustimulation and ondansetron for the treatment of established postoperative nausea and vomiting. Anesthesiology. 2002;97(6): University of Texas at Austin, School of Nursing, Family Nurse Practitioner Program. Evaluation and management of nausea and vomiting in early pregnancy (less than or equal to 20 weeks gestation). Austin, TX: University of Texas at Austin, School of Nursing; May Rosen T, de Veciana M, Miller HS, et al. A randomized controlled trial of nerve stimulation for relief of nausea and vomiting in pregnancy. Obstet Gynecol. 2003;102(1): Jewell D, Young G. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev. 2003;(4):CD Treish I, Shord S, Valgus J, et al. Randomized double-blind study of the Reliefband as an adjunct to standard antiemetics in patients receiving Page 3 of 5
4 moderately-high to highly emetogenic chemotherapy. Support Care Cancer. 2003;11(8): Miller KE, Muth ER. Efficacy of acupressure and acustimulation bands for the prevention of motion sickness. Aviat Space Environ Med. 2004;75(3): White PF, Hamza MA, Recart A, et al. Optimal timing of acustimulation for antiemetic prophylaxis as an adjunct to ondansetron in patients undergoing plastic surgery. Anesth Analg. 2005;100(2): American College of Obstetrics and Gynecology (ACOG). Nausea and vomiting of pregnancy. ACOG Practice Bulletin No.52. Washington, DC: ACOG; April Shiao SY, Dune LS. Metaanalyses of acustimulations: Effects on nausea and vomiting in postoperative adult patients. Explore (NY). 2006;2(3): Ezzo JM, Richardson MA, Vickers A, et al. Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev. 2006;(2):CD Habib AS, Itchon-Ramos N, Phillips-Bute BG, et al. Transcutaneous acupoint electrical stimulation with the ReliefBand for the prevention of nausea and vomiting during and after cesarean delivery under spinal anesthesia. Anesth Analg. 2006;102(2): Arnberger M, Stadelmann K, Alischer P, et al. Monitoring of neuromuscular blockade at the P6 acupuncture point reduces the incidence of postoperative nausea and vomiting. Anesthesiology. 2007;107(6): Zheng LH, Sun H, Wang GN, et al. Effect of transcutaneous electrical acupoint stimulation on nausea and vomiting induced by patient controlled intravenous analgesia with tramadol. Chin J Integr Med. 2008;14(1): Allen TK, Habib AS. P6 stimulation for the prevention of nausea and vomiting associated with cesarean delivery under neuraxial anesthesia: A systematic review of randomized controlled trials. Anesth Analg. 2008;107(4): Frey UH, Scharmann P, Löhlein C, Peters J. P6 acustimulation effectively decreases postoperative nausea and vomiting in high-risk patients. Br J Anaesth. 2009;102(5): Lee A, Fan LT. Stimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting. Cochrane Database Syst Rev. 2009;(2):CD Electrical Stimulation Therapy and Devices, Cigna Medical Coverage (Retrieved August 24, 2016) 29. Electrical Stimulation for Nausea, Vomiting and Motion Sickness (PrimaBella and ReliefBand), Aetna Clinical Policy (Retrieved August 24, 2016) Page 4 of 5
5 AMA CPT Copyright Statement: All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association. This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member s plan in effect as of the date services are rendered. Priority Health s medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion. Priority Health s medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan s ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide. The name Priority Health and the term plan mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc. Page 5 of 5
MEDICAL POLICY No R1 MEDICAL MANAGEMENT OF OBESITY
MEDICAL MANAGEMENT OF OBESITY Effective Date: May 10, 2017 Review Dates: 8/11, 12/11, 2/12, 2/13, 2/14, 2/15, 2/16, 2/17 Date Of Origin: August 10, 2011 Status: Current Note: This medical policy does not
More information*Please see amendment for Pennsylvania Medicaid at the end
1 of 20 Number: 0676 Policy *Please see amendment for Pennsylvania Medicaid at the end of this CPB. Aetna considers transcutaneous electrical acupoint stimulation (prescription version ReliefBand devices)
More informationTRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) FOR THE TREATMENT OF NAUSEA AND VOMITING
MEDICAL POLICY TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) FOR THE TREATMENT OF NAUSEA AND VOMITING Policy Number: 2013T0240K Effective Date: November 1, 2013 Table of Contents COVERAGE RATIONALE...
More informationMEDICAL POLICY No R9 DETOXIFICATION I. POLICY/CRITERIA
DETOXIFICATION MEDICAL POLICY Effective Date: January 1, 2018 Review Dates: 1/93, 2/97, 4/99, 2/01, 12/01, 2/02, 2/03, 1/04, 1/05, 12/05, 12/06, 12/07, 12/08, 12/09, 12/10, 12/11, 12/12, 12/13, 11/14,
More informationMEDICAL POLICY No R4 NEUROPSYCHOLOGICAL AND PSYCHOLOGICAL TESTING
NEUROPSYCHOLOGICAL AND PSYCHOLOGICAL TESTING Effective Date: October 1, 2015 Review Dates: 7/07, 6/08, 6/09, 8/09, 8/10, 8/11, 8/12, 8/13, 8/14, 8/15, 8/16, 8/17 Date Of Origin: July 2007 Status: Current
More informationORTHOGNATHIC SURGERY
ORTHOGNATHIC SURGERY MEDICAL POLICY Effective Date: February 1, 2017 Review Dates: 1/93, 7/95, 10/97, 4/99, 10/00, 8/01, 12/01, 4/02, 2/03, 1/04, 1/05, 12/05, 12/06, 12/07, 12/08, 12/09, 12/10, 12/11,
More informationMEDICAL POLICY No R10 INFUSION SERVICES & EQUIPMENT
INFUSION SERVICES & EQUIPMENT Effective Date: August 1, 2017 Review Dates: 10/95, 12/99, 12/01, 11/02, 11/03, 11/04, 10/05, 10/06, 10/07, 10/08, 10/09, 4/10, 4/11, 4/12, 4/13, 5/14, 5/15, 2/16, 2/17, 5/17
More informationMEDICAL POLICY No R8 EATING DISORDERS POLICY/CRITERIA
EATING DISORDERS MEDICAL POLICY Effective Date: June 27, 2016 Review Dates: 1/93, 8/96, 4/99, 12/01, 12/02, 11/03, 11/04, 10/05, 10/06, 10/07, 8/08, 8/09, 8/10, 8/11, 8/12, 8/13, 5/14, 5/15, 5/16 Date
More informationMEDICAL POLICY No R2 DRUG TESTING
Summary of Changes MEDICAL POLICY DRUG TESTING Effective Date: April 10, 2017 Review Dates: 5/15, 5/16, 11/16, 2/17 Date Of Origin: May 13, 2015 Status: Current Clarifications: Deletions: Additions: Pg.
More informationPostmenopausal Breast Cancer Chemotherapy Responses Antiemetics P6 Accustimulation
Med. J. Cairo Univ., Vol. 78, No. 2, September 205-211, 2010 www.medicaljournalofcairouniversity.com Postmenopausal Breast Cancer Chemotherapy Responses Antiemetics P6 Accustimulation SAYED A. TANTAWY,
More informationMEDICAL POLICY No R3 REFRACTIVE KERATOPLASTY / LASIK
REFRACTIVE KERATOPLASTY / LASIK Effective Date: November 10, 2017 Review Dates: 7/07, 6/08, 6/09, 6/10, 8/10, 8/11, 8/12, 8/13, 8/14, 8/15, 8/16, 8/17 Date Of Origin: July 2007 Status: Current Summary
More informationMaterials and Methods
Anesthesiology 2002; 97:1075 81 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Comparative Efficacy of Acustimulation (ReliefBand ) versus Ondansetron (Zofran ) in
More informationMEDICAL POLICY No R1 GENDER REASSIGNMENT SURGERY
GENDER REASSIGNMENT SURGERY Effective Date: January 1, 2017* Review Dates: 8/15, 8/16, 11/16 Date Of Origin: August 12, 2015 Status: Current *Note: For fully funded commercial (individual or group), this
More informationX.-Y. Yang 1, J. Xiao 2, Y.-H. Chen 2, Z.-T. Wang 2, H.-L. Wang 1, D.-H. He 2 and J. Zhang 1,2, * Abstract
British Journal of Anaesthesia, 115 (6): 883 9 (2015) doi: 10.1093/bja/aev352 Advance Access Publication Date: 27 October 2015 Clinical Practice Dexamethasone alone vs in combination with transcutaneous
More informationSubject: Ondansetron HCl (Zofran ) Injection
09-J0000-98 Original Effective Date: 05/15/09 Reviewed: 07/10/13 Revised: 11/01/15 Subject: Ondansetron HCl (Zofran ) Injection THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationClinical Evaluation Report
Clinical Evaluation Report Product name: TENS device-emeterm Issued Date: July. 17, 2017 Report No.: EmeTerm-20170717 1 The purpose and means of clinical assessment 1.1 Clinical evaluation purposes TENS
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: gastric_electrical_stimulation 9/2003 5/2017 5/2018 5/2017 Description of Procedure or Service Gastric electrical
More informationtens_(transcutaneous_electrical_nerve_stimulator) 7/ / / /2014 This policy is NOT effective until January 13, 2015
Corporate Medical Policy TENS (Transcutaneous Electrical Nerve Stimulator) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tens_(transcutaneous_electrical_nerve_stimulator) 7/1982
More informationMEDICAL POLICY No R1 COMPUTERIZED TOMOGRAPHIC ANGIOGRAPHY CORONARY ARTERIES (CCTA)
COMPUTERIZED TOMOGRAPHIC ANGIOGRAPHY CONARY ARTERIES (CCTA) Effective Date: June 19, 2017 Review Dates: 11/15, 11/16 Date Of Origin: November 11, 2015 Status: Current Summary of Changes Clarifications:
More informationMEDICAL POLICY No R2 OSTEOARTHRITIS OF THE KNEE
OSTEOARTHRITIS OF THE KNEE Effective Date: May 10, 2017 Review Dates: 2/10, 2/11, 2/12, 2/13, 2/14, 2/15, 2/16, 2/17 Date Of Origin: February 10, 2010 Status: Current Summary of Changes Clarifications:
More informationClinical Policy: Netupitant and Palonosetron (Akynzeo) Reference Number: HIM.PA.113 Effective Date: Last Review Date: 05.
Clinical Policy: (Akynzeo) Reference Number: HIM.PA.113 Effective Date: 05.01.17 Last Review Date: 05.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Oral Antiemetics (5-HT3 Antagonists) Reference Number: CP.PMN.11 Effective Date: Last Review Date: 05.18
Clinical Policy: (5-HT3 Antagonists) Reference Number: CP.PMN.11 Effective Date: 09.01.06 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy
More informationThe Use of Nonpharmacologic Techniques to Prevent Postoperative Nausea and Vomiting: A Meta-Analysis
The Use of Nonpharmacologic Techniques to Prevent Postoperative Nausea and Vomiting: A Meta-Analysis Anna Lee, PhD, MPH, and Mary L. Done, FANZCA Department of Anaesthetics, Division of Critical Care,
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 3/1/2012 Most Recent Review Date (Revised): 9/6/2018 Effective Date: 11/1/2018 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER
More informationClinical Policy: Ondansetron (Zuplenz) Reference Number: CP.PMN.45 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zuplenz) Reference Number: CP.PMN.45 Effective Date: 09.01.06 Last Review Date: 02.19 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationMEDICAL POLICY No R5 SURGICAL TREATMENT OF OBESITY
SURGICAL TREATMENT OF OBESITY Effective Date: May 10, 2017 Review Dates: 8/11, 12/11, 2/12, 2/13, 2/14, 11/14, 2/15, 2/16, 2/17 Date Of Origin: August 10, 2011 Status: Current Note: This medical policy
More informationClinical Policy: Acupuncture Reference Number: PA.CP.MP.92
Clinical Policy: Reference Number: PA.CP.MP.92 Effective Date: 01/18 Last Review Date: 11/18 Coding Implications Revision Log Description involves the manual and/or electrical stimulation of thin, solid,
More informationHYSTERECTOMY FOR BENIGN CONDITIONS
HYSTERECTOMY FOR BENIGN CONDITIONS UnitedHealthcare Oxford Clinical Policy Policy Number: SURGERY 104.7 T2 Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE...
More informationClinical Policy: Acupuncture Reference Number: CP.MP.92
Clinical Policy: Reference Number: CP.MP.92 Effective Date: 12/13 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationH F 1 0 T H E R A P Y R E I M B U R S E M E N T R E F E R E N C E G U I D E
HF10 therapy, delivered by the Nevro Senza System, is the high-frequency spinal cord stimulation technology designed to aid in the management of chronic intractable pain of the trunk/limbs without paresthesia.
More informationClinical Policy: Robotic Surgery Reference Number: CP.MP. 207
Clinical Policy: Robotic Surgery Reference Number: CP.MP. 207 Effective Date: 03/05 Last Review Date: 10/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Gastric Electrical Stimulation Reference Number: CP.MP.40
Clinical Policy: Reference Number: CP.MP.40 Effective Date: 09/09 Last Review Date: 10/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationHYSTERECTOMY FOR BENIGN CONDITIONS
UnitedHealthcare Commercial Medical Policy HYSTERECTOMY FOR BENIGN CONDITIONS Policy Number: 2018T0572G Effective Date: September 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationCorporate Medical Policy
Corporate Medical Policy TENS (Transcutaneous Electrical Nerve Stimulator) File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tens_(transcutaneous_electrical_nerve_stimulator) 7/1982
More informationMEDICAL POLICY No R2 COMPUTERIZED TOMOGRAPHIC ANGIOGRAPHY CORONARY ARTERIES (CCTA)
COMPUTERIZED TOMOGRAPHIC ANGIOGRAPHY CONARY ARTERIES (CCTA) Effective Date: January 1, 2018 Review Dates: 11/15, 11/16, 11/17 Date Of Origin: November 11, 2015 Status: Current Summary of Changes Clarifications:
More informationLow-dose Granisetron for the Prevention of Postoperative Nausea and Vomiting
Low-dose Granisetron for the Prevention of Postoperative Nausea and Vomiting John D. Bridges, BS (Pharm)* Cindy B. Nettle, PharmD* Vijaya J. Dugirrala MD Katie J. Suda, PharmD Kevin W. Garey, PharmD *Baptist
More informationPharmacy Medical Necessity Guidelines: Drugs with Quantity Limitations Effective: April 1, 2019
Pharmacy Medical Necessity Guidelines: Drugs with Quantity Limitations Effective: April 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationAnesthesia Reimbursement
This drafted policy is open for a two-week public comment period. This box is not part of the drafted policy language itself, and is intended for use only during the comment period as a means to provide
More informationLumify. Lumify reimbursement guide {D DOCX / 1
Lumify Lumify reimbursement guide {D0672917.DOCX / 1 {D0672917.DOCX / 1 } Contents Overview 4 How claims are paid 4 Documentation requirements 5 Billing codes for ultrasound: Non-hospital setting 6 Billing
More informationConsumer summary: The effect of acupuncture-point stimulation for chemotherapyinduced nausea or vomiting
Consumer summary: The effect of acupuncture-point stimulation for chemotherapyinduced nausea or vomiting A of the effect of acupuncture-point stimulation for chemotherapy-induced nausea or vomiting was
More informationPeripheral Subcutaneous Field Stimulation
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationSympathetic Electrical Stimulation Therapy for Chronic Pain
Sympathetic Electrical Stimulation Therapy for Chronic Pain Policy Number: 015M0076A Effective Date: April 01, 015 RETIRED 5/11/017 Table of Contents: Page: Cross Reference Policy: POLICY DESCRIPTION COVERAGE
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Anzemet) Reference Number: CP.PMN.141 Effective Date: 09.01.06 Last Review Date: 08.18 Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this
More informationMEDICAL POLICY No R8 INFERTILITY DIAGNOSIS AND TREATMENT/ ASSISTED REPRODUCTION/ARTIFICIAL CONCEPTION
INFERTILITY DIAGNOSIS AND TREATMENT/ ASSISTED REPRODUCTION/ARTIFICIAL CONCEPTION Effective Date: June 4, 2015 Review Dates: 1/93, 12/99, 12/01, 11/02, 11/03, 11/04, 10/05, 10/06, 7/07, 6/08, 6/09, 6/10,
More informationPolicy Specific Section:
Payment Policy Anesthesia Services Type: Payment Policy Policy Specific Section: Payment Original Policy Date: Effective Date: October 1, 2010 06-16-2014 Description Anesthesia services consist of the
More informationShow Me the Evidence: Epidurals, PVBs, TAP Blocks Christopher L. Wu, MD Professor of Anesthesiology The Johns Hopkins Hospital
Show Me the Evidence: Epidurals, PVBs, TAP Blocks Christopher L. Wu, MD Professor of Anesthesiology The Johns Hopkins Hospital Overview Review overall (ERAS and non-eras) data for EA, PVB, TAP Examine
More informationMEDICAL POLICY SUBJECT: FEMALE STERILIZATION. POLICY NUMBER: CATEGORY: Contract Clarification
MEDICAL POLICY SUBJECT: FEMALE STERILIZATION PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Crinone, Endometrin ) Reference Number: CP.CPA.03 Effective Date: 11.16.16 Last Review Date: 8.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of
More informationCurrent evidence in acute pain management. Jeremy Cashman
Current evidence in acute pain management Jeremy Cashman Optimal analgesia Best possible pain relief Lowest incidence of side effects Optimal analgesia Best possible pain relief Lowest incidence of side
More informationMP.094.MH Transcutaneous Electrical Nerve Stimulators
MedStar Health, Inc. POLICY AND PROCEDURE MANUAL MP.094.MH Transcutaneous Electrical Nerve Stimulators This policy applies to the following lines of business: MedStar Employee (Select) MedStar MA DSNP
More informationThe Effect of Acupressure on Nausea and Vomiting after Cesarean Section Under Spinal Anesthesia
The Effect of Acupressure on Nausea and Vomiting after Cesarean Section Under Spinal Anesthesia ORIGINAL REPORT Heydar Noroozinia, Alireza Mahoori, Ebrahim Hasani, Mohsen Gerami-Fahim, and Nariman Sepehrvand
More informationPROVIDER POLICIES & PROCEDURES
PROVIDER POLICIES & PROCEDURES REHABILITATION SERVICES The primary purpose of this document is to assist providers enrolled in the Connecticut Medical Assistance Program (CMAP Providers) with the information
More informationPostoperative nausea (PON) is a frequent complication
Efficacy of Acupuncture in Prevention of Postoperative Nausea in Cardiac Surgery Patients Yuliya Korinenko, MD, Ann Vincent, MD, Susanne M. Cutshall, CNS, Zhuo Li, MS, and Thoralf M. Sundt III, MD Mayo
More informationClinical Policy: Trigger Point Injections for Pain Management
Clinical Policy: for Pain Management Reference Number: CP.MP.169 Last Review Date: 08/18 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications
More informationDexamethasone combined with other antiemetics for prophylaxis after laparoscopic cholecystectomy
Original Research Article Dexamethasone combined with other antiemetics for prophylaxis after laparoscopic cholecystectomy T. Uma Maheswara Rao * Associate Professor, Department of Surgery, Konaseema Institute
More informationJ. Basic. Appl. Sci. Res., 2(9) , , TextRoad Publication
2012, TextRoad Publication ISSN 2090-4304 Journal of Basic and Applied Scientific Research www.textroad.com The Evaluation of Post Spinal Anesthesia Nausea and Vomiting Incidence with Lidocaine Versus
More informationName of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor
Name of Policy: Measurement of Long-Chain Omega-3 Fatty Acids in Red Blood Cell Membranes as a Cardiac Risk Factor Policy #: 239 Latest Review Date: July 2010 Category: Laboratory Policy Grade: Active
More informationClinical Policy: Gastric Electrical Stimulation
Clinical Policy: Reference Number: CP.MP.40 Last Review Date: 08/18 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description
More informationClinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145
Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: CP.MP.145 Effective Date: 05/17 Last Review Date: 06/17 See Important Reminder at the end of this policy for important regulatory
More informationCorporate Medical Policy
Antiemetic Injection Therapy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: antiemetic_injection_therapy 5/2015 3/2017 3/2018 3/2017 Description of Procedure
More informationMEDICAL POLICY Acupuncture
POLICY: PG0382 ORIGINAL EFFECTIVE: 12/13/16 LAST REVIEW: 06/12/18 MEDICAL POLICY Acupuncture GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated by each individual
More informationElectric Current Therapy (Iontophoresis) E/I ELECTRIC CURRENT THERAPY (IONTOPHORESIS) HS-237. Policy Number: HS-237. Original Effective Date: 1/9/2014
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationOndansetron combined with ST36 (Zusanli) acupuncture point injection for postoperative vomiting
1 Department of Anesthesiology, Xiangya Hospital, Central South University, Changsha, Hunan, PR China 2 Department of Anesthesiology, Hunan Provincial Tumor Hospital, Changsha, Hunan, PR China 3 National
More informationDiabetes Management, Equipment and Supplies
Coverage Summary Diabetes Management, Equipment and Supplies Policy Number: D-001 Products: UnitedHealthcare Medicare Advantage Plans Original Approval Date: 11/01/2006 Approved by: UnitedHeatlhcare Medicare
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: facet_joint_denervation 6/2009 4/2017 4/2018 4/2017 Description of Procedure or Service Facet joint denervation
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Crinone, Endometrin) Reference Number: CP.CPA.03 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationAnesthesia Processing Guidelines
Anesthesia Processing Guidelines Policy Number: 10.01.511 Last Review: 5/2018 Origination: 10/1988 Next Review: 5/2019 Policy The following guidelines are utilized in processing anesthesia claims: 1) Anesthesia
More informationClinical Policy: Cochlear Implant Replacements Reference Number: CP.MP.14
Clinical Policy: Reference Number: CP.MP.14 Effective Date: 02/09 Last Review Date: 09/17 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory and
More informationName of Policy: Sympathetic Therapy and Bioelectrical Nerve Block or Electroanalgesic Nerve Block for the Treatment of Pain
Name of Policy: Sympathetic Therapy and Bioelectrical Nerve Block or Electroanalgesic Nerve Block for the Treatment of Pain Policy #: 015 Latest Review Date: February 2010 Category: Therapy Policy Grade:
More informationMEDICAL POLICY No R0 THYROID-RELATED PROCEDURES
THYROID-RELATED PROCEDURES Effective Date: October 1, 2018 Review Dates: 05/18 Date Of Origin: May 9, 2018 Status: New This medical policy addresses the following thyroid-related procedures: Screening
More informationUltrasound and Fluoroscopic Paravertebral Facet Joint Injections
Policy Number FAC06222011RP Ultrasound and Fluoroscopic Approved By UnitedHealthcare Medicare Committee Current Approval Date 06/25/2014 IMPORTANT NOTE ABOUT THIS REIMBURSEMENT POLICY This policy is applicable
More informationStimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting (Review)
Stimulation of the wrist acupuncture point P6 for preventing postoperative nausea and vomiting (Review) Lee A, Fan LTY This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationGeneric (Brand) Strength & Dosage form Fml Limit Cost per Rx Notes 5-HT3 Antagonists
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY Nausea LAST REVIEW 9/11/2018 THERAPEUTIC CLASS Gastrointestinal Disorders REVIEW HISTORY 12/16, 11/15, 11/07 LOB AFFECTED
More informationSECTION 1: FEELING SICK
Risks associated with your anaesthetic SECTION 1: This leaflet explains the causes of sickness following anaesthesia and surgery, what can text be done to prevent it occurring, and treatments available
More informationPrevention CINV (highly emetogenic) Prevention PONV
Reviews/Evaluations 5-Hydroxytryptamine3 (5-HT3) Receptor Antagonists Generic Name Brand Name Manufacturer Dolasetron Anzemet Aventis Granisetron Kytril Roche Ondansetron Zofran GlaxoSmithKline I. FDA
More informationFamily Planning Eligibility Program
INDIANA HEALTH COVERAGE PROGRAMS PROVIDER REFERENCE M ODULE Family Planning Eligibility Program L I B R A R Y R E F E R E N C E N U M B E R : P R O M O D 0 0 0 5 3 P U B L I S H E D : N O V E M B E R 2
More informationMedical Necessity Guidelines: Bariatric Surgery
Medical Necessity Guidelines: Bariatric Surgery Effective: July 20, 2017 Clinical Documentation and Prior Authorization Required Applies to: Coverage Guideline, No Prior Authorization Tufts Health Plan
More informationSetting The setting was secondary care. The economic study was carried out in the USA.
The effect of timing of ondansetron administration on its efficacy, cost-effectiveness, and cost-benefit as a prophylactic antiemetic in the ambulatory setting Tang J, Wang B G, White P F, Watcha M F,
More informationClinical Policy: Cochlear Implant Replacements
Clinical Policy: Reference Number: CP.MP.14 Last Review Date: 07/18 Revision Log Coding Implications See Important Reminder at the end of this policy for important regulatory and legal information. Description
More informationMEDICAL POLICY No R8 VENTRICULAR ASSIST DEVICES & ARTIFICIAL HEARTS
VENTRICULAR ASSIST DEVICES & ARTIFICIAL HEARTS Effective Date: January 29, 2018 Review Dates: 8/05, 6/06, 6/07, 6/08, 10/08, 10/09, 10/10, 10/11, 10/12, 10/13, 11/14, 11/15, 11/16, 11/17, 11/18 Date Of
More informationMedical Policy Vertebral Axial Decompression Section 8.0 Therapy Subsection 8.03 Rehabilitation. Description. Related Policies.
8.03.09 Vertebral Axial Decompression Section 8.0 Therapy Subsection 8.03 Rehabilitation Effective Date October 31, 2014 Original Policy Date June 28, 2007 Next Review Date October 2015 Description Vertebral
More informationPERCUTANEOUS FACET JOINT DENERVATION
Status Active Medical and Behavioral Health Policy Section: Surgery Policy Number: IV-95 Effective Date: 10/22/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members should
More informationSurgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea. Original Policy Date
MP 4.01.10 Surgical Interruption of Pelvic Nerve Pathways for Primary and Secondary Dysmenorrhea Medical Policy Section OB/Gyn/Reproduction Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationMEDICAL POLICY No R8 VENTRICULAR ASSIST DEVICES & ARTIFICIAL HEARTS
VENTRICULAR ASSIST DEVICES & ARTIFICIAL HEARTS Effective Date: January 29, 2018 Review Dates: 8/05, 6/06, 6/07, 6/08, 10/08, 10/09, 10/10, 10/11, 10/12, 10/13, 11/14, 11/15, 11/16, 11/17 Date Of Origin:
More informationMEDICAL POLICY. 1 Proprietary Information of YourCare Health Plan
MEDICAL POLICY INTERFERENTIAL STIMULATORS Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized
More informationPost-Dural Puncture Headache. Dr. Jacobs Aurélie Krans Anesthesie 18/03/2016 Kliniek St.-Jan, Brussel
Post-Dural Puncture Headache Dr. Jacobs Aurélie Krans Anesthesie 18/03/2016 Kliniek St.-Jan, Brussel I - PATHOPHYSIOLOGY August Bier (intrathecal cocaïn1898)! first 2 cases PDPH CSF leak trough dura mater
More informationCombined Chiropractic and Acupuncture Services Amendment of the Kaiser Foundation Health Plan, Inc., Evidence of Coverage for SAMPLE GROUP AGREEMENT
EOC #6 - Kaiser Foundation Health Plan, Inc. Southern California Region Combined Chiropractic and Acupuncture Services Amendment of the Kaiser Foundation Health Plan, Inc., Evidence of Coverage for SAMPLE
More informationMAGNETIC RESONANCE IMAGING (MRI) AND COMPUTED TOMOGRAPHY (CT) SCAN SITE OF CARE
UnitedHealthcare Commercial Utilization Review Guideline MAGNETIC RESONANCE IMAGING (MRI) AND COMPUTED TOMOGRAPHY (CT) SCAN SITE OF CARE Guideline Number: URG-13.01 Effective Date: February 1, 2019 Table
More informationDrug Use Criteria: Oral Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting
Texas Vendor Drug Program Drug Use Criteria: Oral Serotonin 5-HT3 Receptor Antagonists for Nausea and Vomiting Publication History Developed September 1996. Revised July 2018; September 2016; June 2015;
More informationAcupuncture during pregnancy Research
Acupuncture during pregnancy Research The information in this handout has been arranged into the following simplified pregnancy categories: Page 2 - Nausea and vomiting Page 3 - Mental health Page 4 -
More informationElectrical Stimulation Device Used for Cancer Treatment
Electrical Stimulation Device Used for Cancer Treatment OPTUNE (NOVOTTF 100A SYSTEM) For any item to be covered by The Health Plan, it must: 1. Be eligible for a defined Medicare or The Health Plan benefit
More informationMeasure Abbreviation: PONV 01 (MIPS 430)
Measure Abbreviation: PONV 01 (MIPS 430) *PONV 01 is built to the specification outlined by the Merit Based Incentive Program (MIPS) 430: Prevention of Post-Operative Nausea and Vomiting (PONV) Combination
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: LA.PPA.12 Effective Date: 02/11 Last Review Date: 01/18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this policy for
More informationClinical Policy: Opioid Analgesics Reference Number: CP.PMN.97 Effective Date: Last Review Date: 02.18
Clinical Policy: Reference Number: CP.PMN.97 Effective Date: 02.11 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationChewing gum for the treatment of postoperative nausea and vomiting: a pilot randomized controlled trial
British Journal of Anaesthesia, 118 (1): 83 9 (2017) doi: 10.1093/bja/aew375 Clinical Practice Chewing gum for the treatment of postoperative nausea and vomiting: a pilot randomized controlled trial J.
More informationClinical Policy: Essure Removal Reference Number: CP.MP.131
Clinical Policy: Reference Number: CP.MP.131 Effective Date: 11/16 Last Review Date: 11/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationPain relief after cesarean section: Oral methadone vs. intramuscular pethidine
Original Article Pain relief after cesarean section: Oral methadone vs. intramuscular pethidine Azar Danesh Shahraki, 1 Mitra Jabalameli, 2 Somayeh Ghaedi 3 1 Associate Professor, Department of Obstetrics
More information